PCSK9 Inhibitors and Real-World Evidence
When to Consider Nonstatin Therapy
Nonstatin Recommendations From Treatment Guidelines
Beyond Statins – AHA/ACC 2018 Lipid Updates
PCSK9 Inhibitors FDA Indications
PCSK9 Inhibitors Dosing and Administration
FOURIER Outcomes Trial Evolocumab
FOURIER Efficacy Outcomes
FOURIER Safety
FOURIER Total Primary Endpoint Events
ODYSSEY Outcomes Study Alirocumab
Alirocumab ODYSSEY Outcomes Trial Results
OSLER-1 Trial
High-Risk Groups for Future ASCVD Events 2018 ACC/AHA Cholesterol Guidelines
FOURIER Trial PAD Subgroup Analysis
Who Will Benefit Most From "Lowest Is Best" Strategy?
Statin-Associated Muscle Symptoms vs Statin Intolerance
Identify Patients With Statin Intolerance
Statins and Glucose Homeostasis Perception vs Evidence
Improving PCSK9 Inhibitor Approval Rates
Navigating the Prior Authorization Process With the Patient
Navigating the Prior Authorization Process Clinical Pearls
Clinical Tips for Therapeutic Management of PCSK9 Inhibitors
Conclusion
Abbreviations
Abbreviations (cont)